Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AgNORs in breast tumours.

C Ceccarelli1, D Trerè, D Santini

  • 1Dipartimento di Scienze Radiologiche e Citoistopatologiche, Università di Bologna, Policlinico S. Orsola, Italy.

Micron (Oxford, England : 1993)
|December 10, 1999
PubMed
Summary

AgNOR protein quantity is a significant prognostic indicator in breast cancer. Image cytometry analysis revealed AgNOR area as an independent predictor of prognosis, alongside Ki67-labelling index, N-status, and tumor size.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Breast (Edinburgh, Scotland)·2026
Same author

The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.

Critical reviews in oncology/hematology·2026
Same author

READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma.

ESMO real world data and digital oncology·2026
Same author

Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care.

Immuno-oncology technology·2026
Same author

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Breast (Edinburgh, Scotland)·2026
Same author

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.

Tumori·2025

Area of Science:

  • Oncology
  • Pathology
  • Biomarkers

Background:

  • Quantitative AgNOR protein distribution is a potential proliferation marker for tumor prognosis.
  • Previous studies show conflicting results regarding AgNOR protein quantity and prognosis in breast cancer.
  • AgNOR area, unlike count, has consistently emerged as an independent prognostic indicator.

Purpose of the Study:

  • To evaluate the prognostic significance of AgNOR proteins in a large cohort of primary breast carcinomas.
  • To correlate AgNOR protein amount, assessed by image cytometry, with established breast cancer prognostic markers and patient survival.

Main Methods:

  • Image cytometry was used to quantify AgNOR protein amount in primary breast carcinomas.
  • Associations between AgNOR protein quantity, other prognostic markers (Ki67-LI, N-status, tumor size), and patient survival were analyzed.

Related Experiment Videos

  • Multivariate analysis was employed to determine the independent prognostic value of AgNOR area.

    • Main Results:

    • A highly significant association was found between AgNOR protein quantity and tumor prognosis.
    • AgNOR area demonstrated independent prognostic value in multivariate analysis, along with Ki67-labelling index (LI), N-status, and tumor size.
    • AgNOR protein area and Ki67-LI were independent predictors in node-positive cases, but not node-negative cases, possibly due to the short follow-up period.

    Conclusions:

    • AgNOR protein quantity is a significant prognostic parameter in breast cancer.
    • AgNOR area, quantified by image cytometry, serves as an independent prognostic indicator in breast cancer.
    • Further research with longer follow-up may clarify the role of AgNOR and Ki67 in node-negative breast cancer prognosis.